文献速递胸部肿瘤

维持阿替利珠单抗对比阿替利珠单抗联合他拉唑帕利在SLFN11阳性广泛期小细胞肺癌中的II期随机研究:S1929

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.
PubMed 文献 · J Thorac Oncol · 2024-11-04

该II期随机研究纳入106例SLFN11阳性(H-score≥1)广泛期小细胞肺癌患者,一线化疗联合阿替利珠单抗后随机接受维持阿替利珠单抗(A组52例)或阿替利珠单抗联合他拉唑帕利(AT组54例)。AT组无进展生存期较A组改善(HR=0.66,80%CI 0.50-0.86,单侧p=0.019),中位PFS分别为2.9个月和2.4个月;总生存期两组无差异(HR=0.98,80%CI 0.71-1.36,单侧p=0.47)。AT组≥3级血液学治疗相关不良事件发生率高于A组(50% vs 4%,p<0.001)。

要点

  • SLFN11阳性ES-SCLC一线化疗免疫后维持AT较A改善PFS(HR=0.66,80%CI 0.50-0.86,单侧p=0.019)。
  • AT组中位PFS 2.9个月,A组2.4个月;OS两组无差异(HR=0.98,80%CI 0.71-1.36,单侧p=0.47)。
  • AT组≥3级血液学治疗相关不良事件50%,A组4%(p<0.001);非血液学≥3级分别为17%和14%。

核心结论

  • 在初始化疗免疫治疗后未进展的SLFN11阳性ES-SCLC患者中,维持AT较A改善PFS。
  • AT组血液学毒性增加,主要为3级贫血,与预期一致。
  • 前瞻性生物标志物选择得到验证,为未来在分子定义的SCLC人群中进行新疗法评估铺平道路。

研究设计与样本

  • II期随机研究,纳入新诊断SLFN11表达(H-score≥1,中心评估)的ES-SCLC患者。
  • 患者一线化疗联合阿替利珠单抗后随机接受维持阿替利珠单抗(A组)或阿替利珠单抗联合他拉唑帕利(AT组)。
  • 主要目标采用单侧10%水平分层log-rank检验比较无进展生存期;目标样本量84例合格患者。
  • 2020年6月15日至2022年12月15日共随机106例合格患者(AT组54例,A组52例)。

主要发现

  • AT组较A组改善PFS(HR=0.66,80%CI 0.50-0.86,单侧p=0.019),中位PFS分别为2.9个月和2.4个月。
  • 两组OS无差异(HR=0.98,80%CI 0.71-1.36,单侧p=0.47)。
  • AT组≥3级非血液学治疗相关不良事件发生率17%,A组14%。
  • AT组≥3级血液学治疗相关不良事件发生率50%,A组4%(p<0.001)。

关键数值与推荐

  • SLFN11表达定义为H-score≥1,由中心评估。
  • 主要终点PFS采用单侧10%水平分层log-rank检验比较。
  • AT组≥3级血液学治疗相关不良事件50% vs A组4%(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether the addition of a poly (adenosine diphosphate-ribose) polymerase inhibitor talazoparib to maintenance immune checkpoint inhibitor atezolizumab after frontline chemoimmunotherapy improved outcomes in patients with Schlafen 11 (SLFN11)-positive extensive-stage SCLC (ES-SCLC). METHODS: Patients with newly diagnosed SLFN11 expressing (H-score ≥ 1, evaluated centrally) ES-SCLC were randomized to maintenance atezolizumab (A) versus atezolizumab plus talazoparib (AT) after frontline chemotherapy plus atezolizumab. The primary objective was to compare progression-free survival (PFS) using a one-sided 10% level stratified log-rank test. Secondary endpoints included objective response rate, overall survival, and toxicity. The target sample size was 84 eligible patients. RESULTS: From June 15, 2020, to December 15, 2022, 106 eligible patients were randomized (54 to AT and 52 to A). Progression-free survival was improved with AT versus A (hazard ratio = 0.66, 80% confidence interval: 0.50-0.86, one-sided p = 0.019) with a median PFS of 2.9 and 2.4 months; overall survival was not different between groups (hazard ratio = 0.98, 80% confidence interval: 0.71-1.36, one-sided p = 0.47). Grade 3 and higher non-hematologic treatment-related adverse events occurred in 17% of patients with AT and 14% of patients with A. Grade 3 and higher hematological treatment-related adverse events were more common in AT (50%) than in A (4%) (p < 0.001). CONCLUSION: Maintenance AT improved PFS in patients with SLFN11-positive ES-SCLC that did not progress after initial chemo-immunotherapy. Hematologic toxicity, primarily grade 3 anemia, was increased with AT, as expected. Prospective biomarker selection was demonstrated, paving the way for future evaluation of novel therapies in molecularly defined SCLC populations.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Karim NA, Miao J, Reckamp KL, et al. Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. J Thorac Oncol. 2024. PMID: 39505259. doi:10.1016/j.jtho.2024.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。